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1. Introduction 
A cardiovascular risk factor (CRF) is a biological characteristic or behaviour that increases 
the possibility of cardiovascular disease (CVD) (1). The concept of risk factors first appeared 
some fifty years ago with the publication of the Framingham Study (2). Since that time, 
advances in the field of epidemiology have made large scale clinical studies possible and 
have led to the identification of a series of cardiovascular disease risk factors that induce the 
formation of atheromatous plaques. The establishment of a specific biological characteristic, 
environmental factor or habit as a CRF requires: a standardised methodology; concordant 
prospective studies; an added effect when various risk factors concur in an individual; and, 
that the modification of the factor (in the case that the factor is modifiable) results in a 
diminution of the risk (3). 
Historically, there has been clear evidence of a series of ‘traditional’ CRFs (Table 1), such as 
hypercholesterolemia, hypertension, hyperglycaemia, nicotine poisoning, sedentarism, etc. 
which have been used in the stratification of individual risk (4). In the recent past, a number 
of important studies have proposed the inclusion of new or ‘emergent’ CRFs in the 
evaluation and stratification of cardiovascular risk and this has implications for preventive 
and therapeutic strategies. 
Numerous documents and reports that include recommendations for the prevention of CVD 
and control of the main cardiovascular risk factors have been published by national and 
international scientific institutions and organisations (from the USA, Europe (5) etc.). 
Following the latest recommendations of the world renowned National Cholesterol 
Education Program (NCEP) (4), Table 1 lists the most significant 'traditional' CRFs whilst 
Table 2 shows the ‘emergent’ factors. Some of the ‘new’ factors have been recognised for 
decades though they have been subject to debate and controversy, and consensus has not 
been reached on their inclusion in cardiovascular risk evaluation. 
The NCEP Panel III identifies three classes of CRFs that influence the possibilities of 
suffering CVD, although only the first two are relevant to the modification of treatment 
objectives: major CRFs, factors linked to lifestyles and emergent risk factors. 
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 Age and sex (men ≥ 45 years old, women ≥ 55 years old) 
 Nicotine poisoning 
 Arterial hypertension (BP ≥ 140/90 mmHg or undergoing antihypertensive treatment) 
 Increase LDL cholesterol  
 Fall in HDL cholesterol (< 40 mg/dl)* 
 Family history of premature coronary heart disease 
Male first degree relatives < 55 years 
Female first degree relatives < 65 years 
 Diabetes mellitus** 
 Lifestyle (overweight/obesity, sedentarism, atherogenic diet)*** 
 * Adapted from Panel III of the National Cholesterol Education Program (4). 
*If HDL cholesterol is ≥ 60 mg/dl, it is considered as a ‘negative’ risk factor”. 
**Diabetes mellitus carries a risk equivalent to a secondary prevention situation. 
***These factors are not computed in the algorithms for stratification of risk.  
AP: arterial pressure; LDL: low density lipoproteins; HDL: high density lipoproteins. 
Table 1. Major (‘traditional’) cardiovascular risk factors, (4). 
Panel III recognises that, in addition to the main CRFs, CVD is influenced by the presence of 
other factors which modification can have a positive effect on some of the major CRFs and 
reduce risk; these therefore represent direct treatment objectives. These factors act through 
other intermediate elements or worsen independent risk factors such as, obesity, sedentarism, 
a family history of premature CVD, psychosocial conditions or being male. Although they do 
not figure in algorithm calculations on the stratification of risk (6), two of them, obesity and 
sedentarism, are considered as causal CRFs by the American Heart Association. 
2. Traditional cardiovascular risk factors 
2.1 Lipid risk factors 
Hypercholesterolemia is one of the main cardiovascular risk factors that are modifiable. The 
Multiple Risk Factor Intervention Trial demonstrated the existence of a continuous and graded 
relationship between cholesterolemia and total mortality and mortality due to ischemic 
heart disease (7). 
The three main classes of lipoproteins are: Low-density lipoproteins (LDL); High-density 
lipoproteins (HDL); and Very low-density lipoproteins (VLDL). There is another class of 
lipoproteins known as Intermediate-density lipoproteins (IDL) that is between VLDL and 
LDL, though in clinical practice, it is included in the LDL category. 
With the exception of HDLs, that play a role in reverse cholesterol transport and therefore 
exercise a vasoprotector action, lipid particles are more atherogenic the more cholesterol 
that they transport. Chylomicrons carry such a small quantity of cholesterol that their 
increase in hyperchylomicronemia (Type I dyslipidemia) is not associated with 
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atherosclerosis lesions. In contrast, with the accumulation of VLDLs, a fifth of which are 
made up of cholesterol, an increase in atherogenesis is observed. Given that LDLs are 
particles with a higher level of cholesterol, they are the main cause of atherogenesis when 
they are in excess. 
Although LDLs receive most attention in clinical management, there is a growing body of 
evidence that indicates that VLDLs play an important role in atherogenesis. 
Levels of HDL cholesterol are inversely related with the risk of CVD; they seem to play a 
protective role against the onset of atherosclerosis as they capture free cholesterol from the 
peripheric tissues such as the cells of the vascular wall. This cholesterol is transformed into 
cholesterol esters, a part of which is transferred to the VLDLs by the cholesterol esters 
transfer proteins (CETP) and returned to the liver by IDLs and LDLs and another part is 
transferred directly to the liver by the HDL particles. The liver reuses the cholesterol for the 
synthesis of VLDLs, for the synthesis of bile salts or excretes it directly into the bile. 
Therefore, HDLs tend to reduce cholesterol levels. 
2.2 Non-lipid risk factors 
Hypertension 
Hypertension is a principal and independent CRF, but its damaging effect is increased when 
associated with other coronary risk factors such as smoking, diabetes and dyslipidemia. The 
Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure defines hypertension as a systolic arterial pressure of 
≥140mmHg or diastolic ≥90mmHg or the need for antihypertensive treatment (8). A number 
of studies, for example the Framingham study, have demonstrated an increase in total 
mortality and cardiovascular risk in cases of increased levels of arterial pressure (diastolic 
and systolic), with a continuous and gradual relationship (9,10,11). The association applies 
to men and women, young and old alike. 
Smoking 
Smoking contributes clearly to CVD. The relationship between smoking and the risk of CVD 
is dose dependent and affects men and women equally. Observational studies suggest that 
stopping smoking leads to a substantial reduction of the risk of a cardiovascular event. 
Diabetes 
Diabetes is defined as the presence of a level of glucose, on an empty stomach, more than, or 
equal to, 126 mg/dL (12). The risk of cardiovascular disease is significantly increased for 
sufferers of diabetes mellitus type 1 and type 2 (13). The increase of risk attributed to 
hyperglycaemia is independent of other risk factors such as obesity, overweight or 
dyslipidemia that are often observed in diabetics.  
80% of diabetes mellitus patient mortality is caused by complications associated with 
atherosclerosis with ischemic heart disease being responsible in 75% of cases (14). In 
addition, the risk of acute myocardial infarction in diabetes mellitus type 2 patients with no 
previous history of myocardial infarction is similar to non-diabetics who have previously 
suffered a heart attack (15). 
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Although it is probable that strict control of diabetes reduces micro-vascular disorders and 
other complications such as renal disease and retinopathies, statistics relative to the effects 
of glycemic control on coronary episodes are uncertain. Diabetics often present 
dyslipidemia, characterised by moderate hypercholesterolemia and hypertriglyceridemia 
with low concentrations of HDL cholesterol that involve increased cardiovascular risk. This 
is frequently associated with central obesity, hyperinsulinism and AHT. Therefore, the 
association of numerous CRFs explains why many individuals already exhibit disorders 
when they are diagnosed with diabetes mellitus. 
3. Emergent cardiovascular risk factors 
Traditional factors can strongly predict the risk of cardiovascular disease but not completely 
(16). Thus, recently new biomarkers have emerged, although their predictive value still 
needs to be validated in multiple cohorts and different populations. 
 
 Lipid Risk Factors 
 Total cholesterol quotient/HDL cholesterol 
 Apolipoproteins 
 HDL subclasses  
 Triglycerides 
 “Small and dense” LDL particles 
 Residual or remnant lipoproteins  
 Non-lipid Risk Factors 
 Markers of inflammation 
 Homocysteinaemia 
 Impaired fasting glycaemia 
 Thrombogenic / hemostatic factors 
 LDL: Low-density lipoproteins; HDL: High-density lipoproteins  
Table 2. Emergent cardiovascular risk factors 
3.1 Apolipoproteins  
Apolipoprotein A 
A apolipoproteins are a group of proteins that are variably distributed among different 
lipoproteins. Apo A-I is the most abundant apolipoprotein in plasma and is nearly 90% of 
the HDL and 60-70% of the protein fraction of the sub-fractions HDL2 and HDL3, 
respectively. Apo A-I is initially synthesised in the liver and intestine as a protein precursor 
which is degraded to its mature form in plasma; it is a simple polypeptide chain that 
contains 243 amino acids. This protein participates in the reverse transport of cholesterol. 
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The apolipoprotein apo A-II is the second highest concentration protein component of HDL, 
although it is absent in the HDL2 sub-fraction and plasma levels do not correlate with HDL-
cholesterol levels.  
The measurement of the concentration of apo A-I in serum perfectly reproduces the 
predictive value of coronary disease of the concentration of HDL in serum. Nevertheless, 
this correlation is not valid in subjects with hypertriglyceridemia, in which the fraction of 
HDL is enriched with triglycerides and cholesterol is almost absent.  
Apolipoprotein B 
B apolipoprotein is a protein of great molecular weight, present in chylomicrons, VLDL, and 
LDL lipoproteins. There are two molecular forms in plasma, apo B-100 (apo B) and apo B-48. 
Apo B is a unique polypeptide chain of 4536 amino acids (one of the biggest plasma proteins), 
synthesised in the liver and secreted in VLDLs. It is quantitatively maintained during the 
conversion of VLDL to IDL until LDL, of which it is the only protein component, and for this 
reason, levels of apo B are correlated with levels of these lipoproteins. Studies have established 
the relationship between B concentrations in serum and cardiovascular risk (17,18,19).  
Given that each particle of VLDL, IDL and LDL only contains one apo B molecule, its 
concentration in serum reflects the risk associated with all these atherogenic particles. 
Although considered as a risk factor by the NCEP, its determination is not recommended in 
clinical practice, due to the unavailability of clinical guides or risk stratification algorithms 
based on its concentration, although it can be useful in some situations. 
Nevertheless, from an experimental point of view, it can offer important additional 
information. The concentration of apo B in serum provides data on the number of particles, 
especially LDL particles, as they contain approximately 90% of total circulating apo B. It has 
been suggested that a LDL/ decreased apo B relationship is an indicator of the 
predominance of small and dense LDL particles (20). 
The estimation of LDL cholesterol using the Friedewald formula is inexact when levels of 
triglycerides are higher than 300mg/dL and, if no validated direct method or 
ultracentrifugation is available, the concentration of apo B can be used as an alternative for 
the stratification of risk and the setting of therapeutic objectives (21). A modification of the 
Friedewald formula has been described for the calculation of LDL cholesterol that includes 
apo B. The LDL cholesterol obtained in this way has been shown to be more independent of 
hypertriglyceridemia than calculations made with the Friedewald formula (22). 
The results of some studies have shown that the relationship between apo B/apo A-I is 
better for evaluating cardiovascular risk than the total cholesterol/HDL cholesterol 
relationship or LDL cholesterol/HDL (23,24). The number of particles and, in particular, the 
balance between them, that is to say, the apo B/apo A-I relationship, may be more 
important than the lipid quantity carried by each particle.  
3.2 Triglycerides 
In spite of the evidence put forward by some epidemiological studies on the relationship 
between hypertriglyceridemia and the incidence of CVD (25,26), the results of other, more 
recent, multivariate works do not allow the definitive classification of triglycerides as an 
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independent CRF (4). This is due to the close relationship between increased levels of 
triglycerides and other lipid CRFs (the presence of residual lipoproteins or remnants of 
VLDLs and chylomicrons in plasma, the predominance of ‘small and dense’ particles of LDL 
in plasma or decreased plasma concentration of HDL cholesterol), non-lipid CRFs 
(hypertension) and emergent CRFs (glucose intolerance, prothrombotic state). The NCEP 
Panel III states that increases in levels of triglycerides (>200mg/dL) are associated with a 
higher risk of CVD. It is also commonly associated with other lipid and non-lipid risk factors 
and indicates that therapeutic objectives should be based on lifestyle changes (loss of 
weight, physical exercise, stopping smoking). 
3.3 Lipoprotein(a) 
In recent years, lipoprotein (a) (Lp(a)) has attracted enormous interest as a cardiovascular 
risk factor (27,28). Lp(a) is a spherical lipoprotein, rich in cholesterol esters and 
phospholipids, it has a composition that is similar to LDL and contains a specific 
glycoprotein, apolipoprotein (a), linked by a disulphide bridge to the apolipoprotein B-100. 
In addition, it has great structural homology to the plasminogen fibrinolytic proenzyme 
(Figure 1) (29).  
A variety of mechanisms that may explain the relationship between lp(a) and cardiovascular 
disease have been described in published works. Firstly, it is argued that as lp(a) is an LDL 
particle it plays a role in the initiation, progression and possible rupture of the atheromatous 
plaque. Secondly, it is suggested that this particle competes with the plasminogen particle 
and inhibits thrombolytic activity (30). Finally, cell line studies with rats have shown that 
lipoprotein (a) inhibits NO synthesis (31). 
 
Fig. 1. Structure of lipoprotein (a). 
Although an increase in the plasma concentration of lp(a) implies a higher risk of CVD, 
mainly in individuals at greater global risk (32), the principal consensus documents, such as 
the NCEP Panel III and the latest European STORE project proposal, do not include it 
among cardiovascular risk factors that are computable for the evaluation of overall risk. This 
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is due to the fact that some studies do not corroborate independent prediction, based on 
lp(a) levels, of suffering CVD (33,34) and there is no evidence that elimination benefits the 
patient (35). 
3.4 Ultra-sensitive CRP 
The inflammatory process characterises all phases of atherothrombotic development. There 
are many studies that relate a variety of elements that intervene in the inflammatory process 
with the risk of CVD. These elements include: the intercellular-1 adhesion molecule (ICAM-
1); the vascular-1 adhesion molecule (VCAM-1); E-selectin; P-selectin; proinflammatory 
cytokines, such as interleucine-6 (IL-6), and the tumor necrosis factor-alpha (TNF-α). All of 
the aforementioned have been shown to be predictors of CRFs (36). In clinical practice, 
difficulties in determining these markers and the short half-life of these molecules in 
circulatory blood mean that it is not possible to include them in the daily clinical routine. Of 
the other markers of inflammation that have been suggested, such as, serum amyloid A, the 
leukocyte count, fibrinogen, nitrotyrosine, myeloperoxidase and c-reactive protein (CRP), 
only the latter has been consolidated as a candidate due to its stability, analysis precision 
and accessibility (37). The AHA (American Heart Association) and CDC (Centers for Disease 
Control) say that of all the markers of inflammation, only ultra-sensitive CRP (US-CRP) has 
the characteristics necessary for use in clinical practice (38). 
Ultra-sensitive CRP (US-CRP) is currently the best characterised inflammation biomarker 
and has been established as a potential marker of cardiovascular risk. US-CRP in plasma is a 
firm candidate for use in clinical practice as it is considered as an independent predictor of 
coronary illness for the general population, for both sexes and for patients that have already 
presented clinical manifestations of CVD (36,37). However, sufficient evidence that reducing 
CRP levels prevents CHD events is lacking (16, 39). 
CRP is a member of the pentraxin family of proteins which are characterised by having a 
pentameric structure and radial symmetry, formed by five protomers of 24 kD and 206 
amino acids that are linked among themselves by non covalent bonds and have the capacity 
to bond to a great variety of substances, such as, phosphocholine, fibronectin, chromatin, 
histones and ribonucleoproteins (40). 
The differentiation of monocytes and macrophages, that takes place during atherosclerotic 
process, frees proinflammatory molecules that include interleukin-6 (IL-6) which activates, 
in the liver, the liberation of inflammation markers like CRP. High levels (>10 mg/dl) are 
registered in bacterial infections though ultra-sensitive analysis can detect very low levels 
(0-3 mg/dl) that are associated with the atherosclerotic process. Their half-life is more than 
24 hours and their blood levels are not altered by diet.  
3.5 Homocysteine 
In the last decade, numerous studies have been published that relate increases 
homocysteinaemia (Hcy) to CVD (41-45). Nevertheless, the mechanism that controls this 
relationship is not completely understood. Homocysteine has a direct cytotoxic effect on 
endothelial cells in cultivation. An alteration in endothelial function has been observed, 
evaluated by echo-Doppler, in individuals with moderate hyperhomocysteinaemia and 
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improvements have been noted on reducing the concentration of homocysteine by means of 
folic acid treatment. It should be remembered that levels of plasma homocysteine are related 
to levels of vitamin B12 and folic acid (46). 
Homocysteine can promote LDL oxidation through the production of reactive oxygen 
species such as hydrogen peroxide and studies have described the promotion of the 
multiplication of smooth muscle cells and a reduction in DNA synthesis in endothelial cells. 
A large number of prospective and retrospective studies support the hypothesis that an 
excess of plasma homocysteine is associated with a higher risk of coronary illness, 
peripheral and cerebrovascular disease (44,47-49). 
3.6 Asymmetric dimethylarginine 
The relationship established between a high concentration of asymmetric dimethylarginine 
(ADMA) and endothelial dysfunction and the possible relationship between high ADMA 
values and the incidence of cardiovascular accidents, has led a number of research groups to 
study the association between high ADMA and death by any cause. 
Some studies indicate that ADMA plasma levels may predict the risk of cardiovascular 
events. In 2001, Valkonen et al. (50) showed that subjects with ADMA levels of more than 
0.62 µmol/L (percentile 75) had almost four times more risk of suffering an acute 
cardiovascular event. Similar results have been described by other authors in cases of 
patients with unstable angina; it was noted that those patients with higher ADMA levels 
(>0,62 µmol/L, percentile 75) had five times more risk of suffering a cardiovascular event 
(51). 
Zoccali et al. (52) showed that in haemodialysis patients, ADMA plasma levels are an 
independent predictor of mortality and cardiovascular risk. In their multivariate study, only 
ADMA and age were significantly predictive, independent of the incidence of 
cardiovascular episodes (such as chest angina and heart attack) and death by any cause. 
Patients whose concentration of plasma ADMA was above the percentile 75, had three times 
more risk of suffering a cardiovascular episode than patients whose initial ADMA levels 
were lower than the average. 
There are currently a number of case studies, controls and prospective clinical trials taking 
place with a variety of patient populations that are aimed at gaining greater understanding 
of the role of ADMA as an independent risk factor for CVD and mortality. The data 
generated by these studies will help in determining the significance of ADMA as a risk 
factor and explore its diagnostic importance in different illnesses and diseases.  
4. Cardiovascular risk factors and physical activity 
There is much research on the effect of physical activity on the alteration of risk factors 
associated with heart disease. The most beneficial effect of exercise is on the level of 
oxidative metabolism which influences levels of lipids in the blood. Aerobic exercise reduces 
levels of triglycerides and total cholesterol and may increase levels of HDLs, especially if 
accompanied by weight loss. Although reductions in total cholesterol and LDL cholesterol 
generated by physical exercise seem to be relatively small (in general, they are less than 
10%), there are important increases in HDL cholesterol and significant reductions in 
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triglycerides. Transversal studies with trained athletes and non-trained subjects 
unequivocally demonstrate that individuals with higher levels of aerobic activity have 
higher HDL levels and lower levels of triglycerides (53), even after a single session of 
exercise (54). Nevertheless, results from longitudinal studies, over relatively long periods of 
time, are much less clear. Many studies on physical exercise have described an increase in 
HDL and a reduction in triglycerides (53,55), but others have described very small changes 
or no changes at all. However, almost all studies have shown that proportions of LDL/HDL 
and total cholesterol/HDL fall after endurance training and this means less cardiovascular 
risk  
There are reliable data that demonstrate the effectiveness of physical exercise on the 
reduction in blood pressure in patients with mild or moderate hypertension. Endurance 
training can reduce systolic and diastolic arterial pressure (DAP) by approximately 10 
mmHg in individuals with moderate essential hypertension. 
With regards to the other traditional cardiovascular risk factors, physical exercise can play a 
role in the reduction and control of weight and in the control of diabetes. Exercise has also 
been shown to be effective in the control and reduction of stress and anxiety (56). 
Whilst the effect of exercise on ‘traditional’ CRFs is well documented, the effect of exercise 
on ‘emergent’ CRFs has not been studied in depth and results are not well known. It must 
not be forgotten that is very important the change in the volume of blood that affects plasma 
concentrations, independently of changes in total lipids, both in terms of lipids and the other 
biochemical parameters expressed as a concentration, for the evaluation of changes 
engendered by physical exercise. The failure to correctly take this factor into account could 
explain some of the controversies concerning studies on CRFs and physical exercise. 
The beneficial effects of exercise, leading to the reduction of levels of apolipoprotein B, have 
been widely reported, but this has not been the case with the relationship between exercise 
and levels of apolipoprotein A-I (57,58). Some authors have found that long-term, regular 
physical exercise does not seem to modify levels of apolipoproteins in comparison with 
sedentary groups (59). There is relatively little information available on levels of lipoprotein 
(a) in young people although some studies have confirmed a favourable relationship 
between regular physical exercise and levels of lipoprotein (a) (57,59), whilst others found 
no difference in lipoprotein (a) concentration between healthy sedentary individuals and 
professional endurance athletes (60). 
The previously mentioned studies have been undertaken by different authors with different 
population groups and there are no published works that, at the same time, analyse the 
influence of intense physical exercise and the influence of continuous physical exercise 
(training) on levels of apolipoproteins A-I, B and lipoproteins (a), in the same population 
group.  
The beneficial effects of physical exercise also seem to be related to the effect on the 
inflammatory process. In the short term, intense physical exercise produces a transitory 
inflammatory response which is reflected in an increase in acute phase reactants and 
cytokines that is proportional to the amount of exercise and muscle damage. Nevertheless, 
regular physical activity (training) is associated with a chronic anti-inflammatory response 
that influences levels of acute phase reactants such as ultra-sensitive CRP and also affects 
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lipids and lipoproteins (61-64). However, Sadepghipour et al. in 2010 found no relationship 
between CRP and physical activity in schoolchildren (65). 
Some factors (BMI, the sex of the subject, the moment when the post-exercise sample is 
taken, diet, etc.), can have an influence on the values measured of ultra-sensitive CRP in 
response to physical exercise (62). Another issue that must be taken into account is that 
many studies that have examined the effects of intense physical exercise on levels of ultra-
sensitive CRP have not made a concentration correction in accordance with the changes in 
plasma volume after exercise (62). Results should be individually corrected according to the 
post-exercise levels of hemoconcentration or hemodilution (66). 
 
With regards to homocysteine, studies with large population groups have shown that 
regular physical exercise can reduce homocysteine plasma levels (47,67,68). However, other 
studies have concluded that intense physical exercise increases levels of Hcy (69,70). More 
recent studies, undertaken by our work group (71), demonstrate increased plasma 
homocysteine levels, both in total and reduced, after intense exercise. This increase is 
independent of the type of exercise and the vitamin levels but could be related to changes in 
renal function (71). The mechanism of this effect is not clearly understood though a study on 
alterations in the redox state of the homocysteine might lead to the comprehension of the 
underlying process. Furthermore, a study on its relationship with plasma concentrations of 
NO, ADMA and their proximate metabolites might lead to an understanding of how intense 
physical exercise produces an increase in levels of homocysteine, as long as regular, 
moderate physical exercise (training) seems to be a beneficial modulator of homocysteine. 
Also related to homocysteine, is the proven fact that regular physical exercise produces a 
series of beneficial effects on oxidative metabolism which result in less oxidative stress and a 
greater defensive capacity against oxidative damage; this is caused by the increase in 
activity of endogenous antioxidant systems and the greater resistance of the LDL particles to 
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oxidation (71,72). All this signifies a reduction in oxidised LDL levels and systematic 
markers of inflammation, as explained by Arquer et al., in 2010 (72). 
In spite of the fact that the role of ADMA as a cardiovascular risk marker is reflected in an 
increasing number of clinical studies and scientific publications, very few studies have 
looked at the effect of intense or sustained (training) physical exercise on ADMA plasma 
levels, with contradictory results. While Schlager et al., in 2011, found that supervised 
exercise training, twice a week during six months, in peripheral arterial disease patients 
decreases ADMA (73), Seljeflot et al., in 2011, observed no effect of 4 weeks of exercise 
training in ADMA concentration in patients with chronic heart failure, speculating that the 
duration of the exercise protocol could be insufficient to find any effects of exercise into 
significant changes in ADMA (74). 
It is therefore recommended that studies should be undertaken on the effect of intense and 
sustained (training) physical exercise on emergent cardiovascular risk factors, especially on 
homocysteine and ADMA. 
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